Form 4: Immunovant CTO Sells Shares for Tax Obligations

Immunovant's Chief Technology Officer, Jay S. Stout, sold 1,585 shares of common stock to cover tax withholding obligations related to vested restricted stock units.

Summary

• Jay S. Stout, Chief Technology Officer of Immunovant, Inc. (IMVT), reported a sale of common stock.
• The transaction involved 1,585 shares sold on October 8, 2025.
• The shares were sold at a weighted average price of $16.30, with prices ranging from $16.06 to $16.48 per share.
• This sale was a 'sell to cover' transaction, mandated by the issuer to satisfy tax withholding obligations from the vesting of 3,436 restricted stock units (RSUs).
• These RSUs were part of a larger grant of 54,978 RSUs on April 2, 2024, and vested on October 2, 2025.
• Following the transaction, Jay S. Stout beneficially owns 203,334 shares of Immunovant common stock.

Sentiment

Score: 5

Explanation: The transaction is a standard 'sell to cover' for tax obligations related to RSU vesting, not indicative of discretionary sentiment or a change in the company's fundamental outlook.

Future Outlook

This Form 4 filing does not contain forward-looking statements or guidance.

Management Comments

• The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of these RSUs.
• The sale is mandated by the Issuer's election to require the satisfaction of tax withholding obligations to be funded by a 'sell to cover' transaction and does not represent a discretionary transaction by the Reporting Person.

Industry Context

This routine insider transaction for tax purposes does not provide specific information to analyze broader industry trends or competitor actions.

Comparison to Industry Standards

• The 'sell to cover' transaction is a standard practice for executives receiving equity compensation across various industries and aligns with common corporate governance practices for managing tax obligations on vested shares.

Key Dates

Recommendation

The reported transaction is a non-discretionary 'sell to cover' sale by a Chief Technology Officer to satisfy tax obligations upon RSU vesting. This is a routine event and does not reflect a change in the officer's confidence in the company or its future prospects, thus it does not warrant a change in investment recommendation based solely on this filing.

Keywords

Immunovant, IMVT, Jay S. Stout, Chief Technology Officer, CTO, insider transaction, Form 4, stock sale, RSU, restricted stock units, tax withholding